Key facts
- It has raised $10.0M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Wuxi Capital, Anhui Guokong Capital, Shuimu Capital, 120 Capital, BioSciKin — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Phagelux
- ·The full record, as it builds
Funding rounds
No funding rounds for Phagelux are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Phagelux
Developer of bacteriophages designed to provide alternatives to antibiotics for multiple fields. The company offers anti-bacterial products across multiple fields utilizing various phage and phage-based technologies, enabling medical users to solve the bacterial problem and provide treatments to various diseases.
- Sector
- Healthcare
- HQ
- Wuxi, China
- Founded
- 2014
- Website
- phagelux.com/
- Ownership
- Privately Held (backing)
Phagelux doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phagelux shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phagelux in its N-PORT filings yet. We sweep new filings monthly.